| cell proliferation |
Increase in the number of cells as a result of cell division
|
| chemotherapy |
The use of chemical agents in the treatment or control of disease or mental disorders
|
| clinical trials |
Medical research studies conducted on human subjects to answer scientific questions and to find better ways to prevent, detect or treat diseases
|
| efficacy |
The ability of a drug to control or cure an illness or disease
|
| FDA |
Food and Drug Administration
|
| formulation |
Incorporation of a drug into a relevant delivery vehicle, such as a gel
|
| GMP |
Good Manufacturing Process
|
| intravenous (IV) |
Situated within, performed within, occurring within, or administered by entering a vein - injection of a drug into the bloodstream through a vein
|
| intra-cavitary (IC) |
Situated or occurring within a body cavity (i.e. treatment characterized by the insertion of substances in a cavity)
|
| IND |
Investigational new drug
|
| kinase |
An enzyme that catalyzes the transfer of phosphate groups from a high-energy phosphate-containing molecule (as ATP or ADP) to a substrate
|
| malignant |
Cancerous - of unfavorable prognosis
|
| melanocytes |
An epidermal cell that produces melanin
|
| metastases, metastasise |
Transfer of a disease-producing agency (e.g. cancer cells) from an original site of disease to another part of the body with development of a similar lesion in a new location
|
| mutation |
A relatively permanent change in hereditary material (gene) involving a physical change in chromosome relations
|
| pathway |
A system of proteins that work together
|
| pharmacokinetics |
The study of the bodily absorption, distribution, metabolism and excretion of drugs
|
| pharmacology |
Evaluation of the activity of the drug in various cell systems and animal models of the disease
|
| phase I |
Clinical trial designed to determine the safety and appropriate dose
|
| phase II |
Clinical trial designed to measure the safety and efficacy
|
| phase III |
Clinical trial designed to test new treatment and measure efficacy as well as safety as compared to the standard of care
|
| progression |
A trend or shift toward a high, more severe state - increase of tumour size (opposite of regression)
|
| receptor |
A chemical group or molecule (as a protein) on the cell surface or in the cell interior that has an affinity for a specific chemical group, molecule, or virus
|
| regimen |
A systematic plan designed to improve and maintain the health of a patient
|
| regression |
A trend or shift toward a lower, less severe or less perfect state - reduction in the size of tumour (opposite of progression)
|
| therapeutic |
Of or relating to the treatment of disease or disorders by remedial agents or methods
|
| therapy (therapies) |
Treatment(s)
|
| toxicity |
The quality, state, or relative degree of being toxic or poisonous
|
| toxicology |
Evaluation of the safety profile of a drug
|
| tumour |
An abnormal benign or malignant mass of tissue that is not inflammatory, arises without obvious cause from cells of preexistent tissue, and possesses no physiological function
|
